Fuquay-Varina, North Carolina, August 16 – The National Institute of Allergy and Infectious Diseases (NIAID) recently awarded $149,388 to Collaborations Pharma, Inc. (CPI) to initiate a partnership with Rutgers aimed at developing a series of compounds for treating tuberculosis (TB), an infectious disease generally affecting the lungs in humans and caused by the bacterium Mycobacterium tuberculosis (Mtb).

Xpert MTB/RIF Ultra, the next-generation test for Mycobacterium tuberculosis, will be with increased sensitivity to aid in detection of patients with smear-negative TB, which is often associated with HIV co-infection.